Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 491 Results

Page 1 of 5012 3 4 5...10 20 30...»Last »

June 2, 2026

DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN^® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy

May 13, 2026

Combined General Meeting of June 3, 2026

May 12, 2026

DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq

April 30, 2026

DBV Technologies Reports First Quarter 2026 Financial Results

April 2, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026

March 26, 2026

DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document

March 26, 2026

DBV Technologies Reports Full Year 2025 Financial Results and Business Update

March 24, 2026

DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

March 4, 2026

DBV Technologies to Participate in Upcoming March Investor Conferences

March 3, 2026

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026

Page 1 of 5012 3 4 5...10 20 30...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Your California Privacy Rights

Scroll to Top